>Go!

R&D Areas of Focus

Allergan is Focused on Researching and Developing New Therapies

Medical Aesthetics & Dermatology

In Medical Aesthetics & Dermatology, Allergan is focused on researching and developing new therapies for skin conditions such as rosacea, acne, fat reduction in the submental and other body areas, facial lines, alopecia and facial volume. Lead programs include Oxymetazoline (Rosacea), Aczone (Acne), Volift/Volite, and new indications for on-market products such as Botox, Voluma and Kybella. 

Eye Care

Allergan’s R&D efforts in Eye Care are focused on advancing innovation in the treatment of dry eye disease, glaucoma and conditions that impact the back of the eye, including retinal conditions. Lead programs include Oculeve, new delivery and formulations of Restasis, XEN 45, Bimatoprost SR, Brimonidine SR for dry age-related macular degeneration and the DARPin portfolio of programs.  

Central Nervous System (CNS)

In CNS, Allergan is advancing programs to treat critical conditions such as Major Depressive Disorder (MDD), Migraine and Alzheimer’s disease. Key programs include rapastinel (MDD) Ubrogepant (Acute Migraine), M1, M4 and M1/M4 Agonists (Alzheimer’s disease) and an NR2Br Antagonist (OCD/Autism).

Gastroenterology 

Allergan’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years. 

Women’s Health and Urology

In Women’s Health and Urology, Allergan is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray)  as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.

Anti-Infectives 

Allergan’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. Allergan is also focused on adding new innovative programs throughout its seven therapeutic areas.